Loyal, a biotech company pioneering longevity drugs for dogs, today announced that it has successfully completed its Series B funding round, securing $45 million in investment. The round was led by Bain Capital Ventures. This brings total funding raised by Loyal to more than $125 million since its founding in 2019 and includes a $12 million credit facility from Bridge Bank, part of Western Alliance Bank.

Most major existing investors from Loyal's previous financings - including Khosla Ventures, First Round Capital, Box Group, Collaborative Fund, Quiet Capital, and Todd & Rahul's Angel Fund - participated in this round. Bain Capital Ventures and Valor Equity Partners are new investors.

Loyal is a biotech startup developing the first drugs intended to help dogs live longer, healthier lives. By targeting the underlying mechanisms of aging, Loyal hopes to extend the lifespan of dogs and maintain their quality of life as they age.